Company: TVRD
Filing Date: 2025-05-13
Form Type: 8-K
Source: 0001104659-25-047856
Chunk: 0

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02.

Results of Operations and Financial Condition.

On May 13,
2025, Tvardi Therapeutics, Inc. (formerly Cara Therapeutics, Inc.) (the “ Company”) issued a press release announcing its financial
results for the fiscal quarter ended March 31, 2025. A copy of the Company’s press release dated May 13, 2025 is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.

The information
contained herein and the accompanying Exhibit 99.1 is being furnished under “ Item 2.02 Results of Operations and Financial Condition”
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed
incorporated by reference in any filing with the Securities and Exchange Commission (the “ SEC”) made by us, whether made before
or after the date hereof, regardless of any general incorporation language in such filing.

Item 4.01. Changes in
Registrant’s Certifying Accountant.

(a)
Dismissal of Independent Registered Public Accounting Firm

On May 12,
2025, the Audit Committee (the “ Audit Committee”) of the Board of Directors of the Company dismissed Ernst & Young LLP
(“ EY”) as the Company’s independent registered public accounting firm, with such dismissal to become effective immediately
following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 with the SEC (the “ Effective
Time”).

EY’s
audit reports on the Company’s consolidated financial statements as of and for the years ended December 31, 2024 and 2023 did not
contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting
principles.

During the
Company’s fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through May 12, 2025: (1) there were
no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304) with EY on
any matter of accounting principles or practices, financial statement disclosure, or auditing scope